LH Labcorp
NYSE · SEC CIK 920148 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $13.70M 20 sales by 10 insiders
- Filings on record
- 414 since 2021-08-03, latest 2026-09-03 08:21
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Schechter Adam H | Pres, CEO, Dir | — | $8.44M |
| Parham Richelle P | Dir | — | $1.78M |
| Wilkinson Peter J | SVP, CAO | — | $1.06M |
| ANDERSON KERRII B | Dir | — | $954.1K |
| Caveney Brian J | EVP, CMO, CSO, Pres of ED | — | $429.5K |
| Meltzer Jonathan C | EVP, Ops | — | $298.8K |
| Summy Amy B. | EVP, CMO | — | $283.4K |
| Kyle Kathryn W | EVP, CLO | — | $227.4K |
| van der Vaart Sandra D | EVP, Corp. Affairs | — | $156.0K |
| Vaughn Bryan T | EVP, Pres, Diagnostics | — | $67.0K |
Transactions 566
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-08 | 2022-02-04 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +300 | 5,587 | +6% | — |
| D | 2022-02-08 | 2022-02-07 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale+OE | $277.38 | -218 | 5,287 | -4% | -$60.5K |
| D | 2022-02-08 | 2022-02-04 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $277.48 | -165 | 9,647 | -2% | -$45.8K |
| D | 2022-02-08 | 2022-02-04 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +560 | 9,812 | +6% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +560 | 10.1K | +6% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $277.48 | -165 | 9,912 | -2% | -$45.8K |
| D | 2022-02-08 | 2022-02-04 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $277.48 | -109 | 14.6K | -0.7% | -$30.2K |
| D | 2022-02-08 | 2022-02-04 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +373 | 14.8K | +3% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +150 | 1,236 | +14% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $277.48 | -53 | 1,183 | -4% | -$14.7K |
| D | 2022-02-08 | 2022-02-04 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +3,507 | 17.9K | +24% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $277.48 | -1,412 | 16.5K | -8% | -$391.8K |
| D | 2022-02-08 | 2022-02-07 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale+OE | $277.38 | -204 | 6,606 | -3% | -$56.6K |
| D | 2022-02-08 | 2022-02-04 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +560 | 6,962 | +9% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $277.48 | -152 | 6,810 | -2% | -$42.2K |
| D | 2022-02-08 | 2022-02-04 | LH | Seltz Judith C | EVP, CHRO | F - Tax | $277.48 | -85 | 1,377 | -6% | -$23.6K |
| D | 2022-02-08 | 2022-02-04 | LH | Seltz Judith C | EVP, CHRO | M - OptEx | — | +280 | 1,462 | +24% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +267 | 582 | +85% | — |
| D | 2022-02-08 | 2022-02-04 | LH | Summy Amy B. | EVP, CMO | F - Tax | $277.48 | -83 | 499 | -14% | -$23.0K |
| D | 2022-02-04 | 2022-02-02 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +443 | 9,396 | +5% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $273.18 | -144 | 9,252 | -2% | -$39.3K |
| D | 2022-02-04 | 2022-02-03 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale+OE | $271.81 | -161 | 6,402 | -2% | -$43.8K |
| D | 2022-02-04 | 2022-02-02 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $273.18 | -121 | 6,562 | -2% | -$33.1K |
| D | 2022-02-04 | 2022-02-02 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +443 | 6,684 | +7% | — |
| D | 2022-02-04 | 2022-02-02 | LH | BELINGARD JEAN-LUC | Dir | M - OptEx | — | +771 | 16.3K | +5% | — |
| D | 2022-02-04 | 2022-02-02 | LH | BELINGARD JEAN-LUC | Dir | F - Tax | $273.18 | -78 | 16.3K | -0.5% | -$21.3K |
| D | 2022-02-04 | 2022-02-02 | LH | Gilliland Dwight Gary | Dir | M - OptEx | — | +771 | 7,023 | +12% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $273.18 | -147 | 9,517 | -2% | -$40.2K |
| D | 2022-02-04 | 2022-02-02 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +443 | 9,664 | +5% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Parham Richelle P | Dir | M - OptEx | — | +771 | 6,845 | +13% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +116 | 1,127 | +11% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $273.18 | -41 | 1,086 | -4% | -$11.2K |
| D | 2022-02-04 | 2022-02-02 | LH | Kong Garheng | Dir | M - OptEx | — | +771 | 10.2K | +8% | — |
| D | 2022-02-04 | 2022-02-02 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $273.18 | -103 | 14.4K | -0.7% | -$28.1K |
| D | 2022-02-04 | 2022-02-02 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +296 | 14.5K | +2% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Williams R Sanders | Dir | M - OptEx | — | +771 | 7,003 | +12% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Davis Jeffrey A. | Dir | M - OptEx | — | +771 | 1,930 | +67% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Seltz Judith C | EVP, CHRO | F - Tax | $273.18 | -76 | 1,182 | -6% | -$20.8K |
| D | 2022-02-04 | 2022-02-02 | LH | Seltz Judith C | EVP, CHRO | M - OptEx | — | +220 | 1,258 | +21% | — |
| D | 2022-02-04 | 2022-02-02 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +236 | 5,523 | +4% | — |
| D | 2022-02-04 | 2022-02-03 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale+OE | $271.81 | -172 | 5,287 | -3% | -$46.8K |
| D | 2022-02-04 | 2022-02-02 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $273.18 | -64 | 5,459 | -1% | -$17.5K |
| D | 2022-02-04 | 2022-02-02 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +766 | 43.2K | +2% | — |
| D | 2022-02-04 | 2022-02-02 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $273.18 | -236 | 43.0K | -0.5% | -$64.5K |
| DM | 2022-02-04 | 2021-12-14 | LH | ANDERSON KERRII B | Dir | G - Gift | $0.00 | -1,550 | 20.0K | -7% | $0 |
| D | 2022-02-04 | 2022-02-02 | LH | ANDERSON KERRII B | Dir | M - OptEx | — | +771 | 19.5K | +4% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Summy Amy B. | EVP, CMO | F - Tax | $273.18 | -77 | 315 | -20% | -$21.0K |
| D | 2022-02-04 | 2022-02-02 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +220 | 392 | +128% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +2,773 | 15.2K | +22% | — |
| D | 2022-02-04 | 2022-02-02 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $273.18 | -803 | 14.4K | -5% | -$219.4K |
| D | 2022-02-04 | 2022-02-02 | LH | NEUPERT PETER M | Dir | M - OptEx | — | +771 | 6,754 | +13% | — |
| M | 2021-12-17 | 2021-12-15 | LH | Gilliland Dwight Gary | Dir | S - Sale | $302.26 | -500 | 6,295 | -7% | -$151.1K |
| D | 2021-11-09 | 2021-11-05 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $274.84 | -899 | 6,240 | -13% | -$247.1K |
| D | 2021-11-09 | 2021-11-05 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +2,010 | 7,140 | +39% | — |
| D | 2021-11-09 | 2021-11-05 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +2,010 | 10.1K | +25% | — |
| D | 2021-11-09 | 2021-11-05 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $274.84 | -899 | 9,182 | -9% | -$247.1K |
| D | 2021-11-03 | 2021-11-01 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $288.78 | -898 | 8,953 | -9% | -$259.3K |
| D | 2021-11-03 | 2021-11-01 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +2,007 | 9,851 | +26% | — |
| D | 2021-11-03 | 2021-11-01 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $288.78 | -4,034 | 42.4K | -9% | -$1.16M |
| D | 2021-11-03 | 2021-11-01 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +9,024 | 46.5K | +24% | — |
| D | 2021-11-03 | 2021-11-01 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +2,007 | 13.3K | +18% | — |
| D | 2021-11-03 | 2021-11-01 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $288.78 | -886 | 12.4K | -7% | -$255.9K |
| D | 2021-09-17 | 2021-09-15 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | $84.86 | +4,500 | 9,765 | +85% | +$381.9K |
| D | 2021-09-17 | 2021-09-15 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale+OE | $296.78 | -4,500 | 5,265 | -46% | -$1.34M |
| D | 2021-08-03 | 2021-08-02 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $297.61 | -15 | 1,011 | -1% | -$4,464 |
| D | 2021-08-03 | 2021-08-01 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +50 | 1,026 | +5% | — |
Purchase Sale Sale after option exercise All abbreviations